Issue 18, 2011

Inhibitors of an essential mycobacterialcell walllipase (Rv3802c) as tuberculosis drug leads

Abstract

The first targeted inhibitors of an essential M. tuberculosis cell wall lipase, Rv3802c, are described. Lead compounds exhibited nanomolar inhibition of the enzyme, and encouraging antibacterial activity against M. tuberculosis in vitro, supporting Rv3802c as a novel TB drug target.

Graphical abstract: Inhibitors of an essential mycobacterial cell wall lipase (Rv3802c) as tuberculosis drug leads

Supplementary files

Article information

Article type
Communication
Submitted
16 Dec 2010
Accepted
17 Feb 2011
First published
07 Mar 2011

Chem. Commun., 2011,47, 5166-5168

Inhibitors of an essential mycobacterial cell wall lipase (Rv3802c) as tuberculosis drug leads

N. P. West, K. M. Cergol, M. Xue, E. J. Randall, W. J. Britton and R. J. Payne, Chem. Commun., 2011, 47, 5166 DOI: 10.1039/C0CC05635A

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements